4//SEC Filing
PANOFF MARC L 4
Accession 0001304340-25-000006
CIK 0001691082other
Filed
Sep 28, 8:00 PM ET
Accepted
Sep 29, 8:16 PM ET
Size
28.1 KB
Accession
0001304340-25-000006
Insider Transaction Report
Form 4
PANOFF MARC L
Senior Vice President, Finance
Transactions
- Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-09-10−1,255→ 0 totalExercise: $69.72Exp: 2030-08-30→ Common Stock (1,255 underlying) - Award
Employee Stock Option (Right to Buy)
2025-09-10+90,525→ 90,525 totalExercise: $15.00Exp: 2035-09-09→ Common Stock (90,525 underlying) - Award
Employee Stock Option (Right to Buy)
2025-09-10+3,944→ 3,944 totalExercise: $15.00Exp: 2028-11-13→ Common Stock (3,944 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-09-10−7,171→ 0 totalExercise: $41.84Exp: 2034-06-26→ Common Stock (7,171 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-09-10−3,944→ 0 totalExercise: $64.15Exp: 2028-11-13→ Common Stock (3,944 underlying) - Award
Employee Stock Option (Right to Buy)
2025-09-10+896→ 896 totalExercise: $15.00Exp: 2029-12-22→ Common Stock (896 underlying) - Award
Employee Stock Option (Right to Buy)
2025-09-10+1,255→ 1,255 totalExercise: $15.00Exp: 2030-08-30→ Common Stock (1,255 underlying) - Award
Employee Stock Option (Right to Buy)
2025-09-10+7,171→ 7,171 totalExercise: $15.00Exp: 2034-06-26→ Common Stock (7,171 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-09-10−896→ 0 totalExercise: $69.72Exp: 2029-12-22→ Common Stock (896 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2025-09-10−14,343→ 0 totalExercise: $41.84Exp: 2033-08-24→ Common Stock (14,343 underlying) - Award
Employee Stock Option (Right to Buy)
2025-09-10+14,343→ 14,343 totalExercise: $15.00Exp: 2033-08-24→ Common Stock (14,343 underlying)
Footnotes (5)
- [F1]Immediately exercisable.
- [F2]The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.
- [F3]One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
- [F4]One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
- [F5]One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Documents
Issuer
LB PHARMACEUTICALS INC
CIK 0001691082
Entity typeother
Related Parties
1- filerCIK 0001304340
Filing Metadata
- Form type
- 4
- Filed
- Sep 28, 8:00 PM ET
- Accepted
- Sep 29, 8:16 PM ET
- Size
- 28.1 KB